# OpenEvidence

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/openevidence

- Industry: Healthcare IT
- Headquarters: Miami, US
- Website: www.openevidence.com
- Total disclosed funding: $655M
- Latest round: Series D (Jan 21, 2026)
- Investors on record: 17

## About

OpenEvidence Inc. is a company focused on improving healthcare by providing a platform that aggregates clinical findings and multimedia resources for healthcare professionals, enhancing their access to crucial medical insights.

Based in Miami, US and founded in 2021, OpenEvidence Inc. is dedicated to providing an extensive platform for healthcare professionals to access relevant clinical findings. Daniel Nadler is the CEO of the company, who co-founded the company along with Zachary Ziegler. In October 2026, OpenEvidence Inc. raised USD 250 million in venture funding co-led by new investors Andreessen Horowitz and Byers Capital.

OpenEvidence primarily offers a platform designed to facilitate access to multimedia and clinical findings, specifically for healthcare professionals. The platform aggregates data from reputable sources such as The New England Journal of Medicine, providing a comprehensive repository of clinical insights and research findings. It serves a diverse customer base, including physicians, researchers, and healthcare organizations within the United States, focusing on enhancing clinical decision-making and improving patient outcomes through evidence-based data access.

OpenEvidence generates revenue by offering its platform free of charge to healthcare professionals, fostering collaborations with institutions and organizations to enhance the dissemination of medical research. The firm’s business model emphasizes engagement and retention rather than traditional transactional revenue, establishing itself as a critical tool for healthcare professionals to access essential medical insights and data.

## Funding rounds

- Series D, Jan 21, 2026, $225M — Blackstone Group, Kleiner Perkins, Meritech Capital Partners, Hong Shan, Mayo Clinic, Greycroft, GV, Coatue Management, Alkeon Capital Management, DST Global, Thrive Capital, ICONIQ Capital, Breyer Capital, Craft Ventures, Bond, Goanna Capital, Conviction
- Series C, Oct 20, 2025, $200M — Blackstone Group, Kleiner Perkins, Hong Shan, GV, Coatue Management, Thrive Capital, Craft Ventures, Bond
- Series B, Jul 15, 2025, $155M — Kleiner Perkins, Hong Shan, Greycroft, GV, Coatue Management, Thrive Capital, Conviction
- Series A, Feb 19, 2025, $75M — Hong Shan

## Investors

- Hong Shan — Series A, Series B, Series C, Series D
- Kleiner Perkins (https://capitalatlas.ai/funds/kleiner-perkins) — Series B, Series C, Series D
- Greycroft (https://capitalatlas.ai/funds/greycroft) — Series B, Series D
- GV (https://capitalatlas.ai/funds/gv) — Series B, Series C, Series D
- Coatue Management (https://capitalatlas.ai/funds/coatue-management) — Series B, Series C, Series D
- Thrive Capital (https://capitalatlas.ai/funds/thrive-capital) — Series B, Series C, Series D
- Conviction (https://capitalatlas.ai/funds/conviction) — Series B, Series D
- Blackstone Group (https://capitalatlas.ai/funds/blackstone-group) — Series C, Series D
- Craft Ventures (https://capitalatlas.ai/funds/craft-ventures) — Series C, Series D
- Bond (https://capitalatlas.ai/funds/bond) — Series C, Series D
- Meritech Capital Partners (https://capitalatlas.ai/funds/meritech-capital-partners) — Series D
- Mayo Clinic — Series D
- Alkeon Capital Management (https://capitalatlas.ai/funds/alkeon-capital-management) — Series D
- DST Global (https://capitalatlas.ai/funds/dst-global) — Series D
- ICONIQ Capital (https://capitalatlas.ai/funds/iconiq-capital) — Series D
- Breyer Capital (https://capitalatlas.ai/funds/breyer-capital) — Series D
- Goanna Capital (https://capitalatlas.ai/funds/goanna-capital) — Series D